Phase 3 TRIUMPH readouts show dose-dependent mean weight loss up to ~30% at 104 weeks in obesity and ~21% in T2D, with ...
The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA. The FDA has granted an accelerated approval to the regimen ...
The Women’s Health Initiative, launched in 1991 across 40 centers with >161,000 participants, materially influenced practice ...
A large UK cohort study found atopic dermatitis raises the risk of shingles by 28%, with the steepest risk in severe disease ...
Forecasted cost growth was highest in fully insured arrangements, consistent with constrained data rights; only about 60% felt able to audit full claims files. Employers with complete claims data ...
A narrative review found obesity independently worsens psoriasis severity and blunts response to fixed-dose biologics, ...
The disparity in outcomes between pediatric and young adult patients with ALL is multifactorial, explained Emily K. Curran, MD.
Brittany G. Craiglow, MD, FAAD, discusses JAK inhibitor hesitancy in pediatric alopecia areata, boxed warnings, and why step ...
Effective October 13, 2026, federal financial participation is barred for specified pharmacologic and surgical interventions for Medicaid beneficiaries under 18 and CHIP enrollees under 19. CMS ...
Nationwide difference-in-differences analysis (IPTW-adjusted) compared 180-day preadmission vs 180-day postdischarge HEDIS ...
Phase 2 data show promising antiviral activity with tobevibart plus elebsiran in hepatitis D, supporting further evaluation in the phase 3 ECLIPSE program. First identified in the late 1970s by ...
Post–CAR T relapse in MCL is associated with median PFS ~2.5 months and OS ~5.4 months, underscoring a high-need salvage setting without an established standard. Relapse biopsy demonstrated retained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results